You are here: Industry Insights > Remdesivir

News List

To Win the Fight against COVID-19 in the Future, How To Make a Breakthrough in the R&D of New Drug? PharmaSources/Professor in medical field
March 21, 2022
Recently, with the continuous evolution and spread of Novel Coronavirus variant (including Delta-related variant viruses) all over the world, the mortality rate in some areas has a tendency to increase.
Remdesivir ineffective against COVID-19? Perhaps it is not taken the right way PharmaSources/Shanghai Xiaoyaoshi
January 07, 2021
Remdesivir ineffective against COVID-19? Has a bleak prospect?! Perhaps it is not taken the right way.
Developments and Critical Issues of COVID-19 Treatment/Vaccine R&D in China PharmaSources.com
September 21, 2020
It has been over half a year since the pandemic first outbroke in Wuhan of China. This article is to review and update what we know about treatments and vaccines development, and critical issues in the fight against the pandemic.
Remdesivir, the First Experimental Medication to Treat 2019-novel Coronavirus (COVID-19) Infection Lin Zhang
April 23, 2020
Japan Approves Remdesivir For Use On Severe COVID-19 Patients.
Emmes Announces Completion of Third ACTT Clinical Trial for COVID-19 prnewswire
November 30, 2021
Emmes today announced that it conducted the data and statistical analysis for the third iteration of the Adaptive COVID-19 Treatment Trial (ACTT-3), using its proprietary Advantage eClinical system.
Dexamethasone Underused for Adults Hospitalized With COVID-19 drugs
August 17, 2021
For adults hospitalized with COVID-19, dexamethasone and remdesivir use increased over time, although dexamethasone is still somewhat underused, according to a study published online Aug. 17 in the Annals of Internal Medicine.
Centre increases supply of essential drugs for COVID expresspharma
August 05, 2021
The availability of all major drugs required for the management of COVID-19 was regularly monitored through weekly surveys of retail pharmacies, said Health Minister.
Rethinking Remdesivir firstwordpharma
August 04, 2021
Remdesivir is an antiviral drug originally discovered as part of a program to develop antiviral agents with activity against novel emerging viruses.
FDA Authorizes New Standalone Treatment for COVID-19 americanpharmaceuticalreview
July 30, 2021
The U.S. FDA revised the Emergency Use Authorization (EUA) for baricitinib (sold under the brand name Olumiant) now authorizing baricitinib alone for the treatment of COVID-19 in hospitalized adults and pediatric patients two years of age or older ...
FDA expands EUA for Lilly-Incyte’s baricitinib as Covid-19 monotherapy pharmaceutical-technology
July 30, 2021
The US Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for Eli Lilly and Incyte’s drug, baricitinib, for Covid-19 treatment with or without remdesivir.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page